Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jun 18:54:101359.
doi: 10.1016/j.lanepe.2025.101359. eCollection 2025 Jul.

Targeting smouldering neuroinflammation in multiple sclerosis: insights from tolebrutinib clinical trials

Maria Trojano  1 , Damiano Paolicelli  1
Affiliations

Targeting smouldering neuroinflammation in multiple sclerosis: insights from tolebrutinib clinical trials

Maria Trojano et al. Lancet Reg Health Eur. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

MT has served on scientific advisory boards for Biogen, Novartis, Roche, Merck, Sandoz and BMS; has received speaker honoraria and support for attending meetings and/or travel from Biogen, Roche, Sanofi, Merck, Alexion, Sandoz and Novartis. DP has served on scientific advisory boards for Novartis, Merck, Sandoz, Sanofi, and Biogen; has received speaker honoraria and support for attending meetings and/or travel from Biogen, Sandoz, Roche, Merck, Novartis, Sanofi, Alexion.

References

    1. Kuhlmann T., Moccia M., Coetzee T., et al. International Advisory Committee on Clinical Trials in Multiple Sclerosis Multiple sclerosis progression: time for a new mechanism-driven framework. Lancet Neurol. 2023;22(1):78–88. doi: 10.1016/S1474-4422(22)00289-7. Epub 2022 Nov 18. - DOI - PMC - PubMed
    1. Oh J., Arnold D.L., Cree B.A.C., et al. Tolebrutinib Phase 3 GEMINI 1 and 2 Trial Group Tolebrutinib versus teriflunomide in relapsing multiple sclerosis. N Engl J Med. 2025 doi: 10.1056/NEJMoa2415985. [Epub ahead of print] - DOI - PubMed
    1. Fox R.J., Bar-Or A., Traboulsee A., et al. HERCULES Trial Group Tolebrutinib in nonrelapsing secondary progressive multiple sclerosis. N Engl J Med. 2025 doi: 10.1056/NEJMoa2415988. [Epub ahead of print] - DOI - PubMed
    1. Gruber R.C., Wirak G.S., Blazier A.S., et al. BTK regulates microglial function and neuroinflammation in human stem cell models and mouse models of multiple sclerosis. Nat Commun. 2024;15(1) doi: 10.1038/s41467-024-54430-8. - DOI - PMC - PubMed
    1. Krämer J., Wiendl H. Bruton tyrosine kinase inhibitors in multiple sclerosis: evidence and expectations. Curr Opin Neurol. 2024;37(3):237–244. doi: 10.1097/WCO.0000000000001269. Epub 2024 Mar 27. - DOI - PubMed

LinkOut - more resources